XL-protein GmbH
Research - Freising, Bavaria, Germany
XL-protein GmbH Employees
XL-protein GmbH Details
XL-protein develops and commercializes its proprietary PASylation® technology to extend the plasma half-life of biopharmaceuticals. The genetic fusion (or chemical conjugation) with conformationally disordered amino acid sequences composed of the three small residues Pro, Ala, and/or Ser ('PASylation') provides a simple way to attach a solvated biopolymer with large hydrodynamic volume to a therapeutic protein or peptide. This polypeptide adopts a bulky random coil structure, which significantly increases the size of the biopharmaceutical. By this means the typically rapid clearance of the biologically active component via kidney filtration is retarded by 1-2 orders of magnitude, depending on the length of the PAS tag. Compared with other strategies to prolong the plasma half-life of biologics the PASylation technology provides numerous advantages.
XL-protein GmbH Technologies
E-commerce Platforms
Woo Commerce
Load Balancers
Apache
Payments
Paypal
Tag Management
Google Tag Manager
Fonts
Google Font API
Other
Mobile Friendly